Allworth Financial LP Has $7.86 Million Stock Position in Zoetis Inc. $ZTS

Allworth Financial LP lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 32.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 62,429 shares of the company’s stock after purchasing an additional 15,199 shares during the period. Allworth Financial LP’s holdings in Zoetis were worth $7,855,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in ZTS. Global Wealth Strategies & Associates acquired a new position in Zoetis during the fourth quarter worth $25,000. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Zoetis during the 3rd quarter worth about $31,000. Lodestone Wealth Management LLC acquired a new position in shares of Zoetis during the 4th quarter worth about $30,000. Holos Integrated Wealth LLC bought a new stake in shares of Zoetis in the 4th quarter valued at about $32,000. Finally, Board of the Pension Protection Fund bought a new stake in shares of Zoetis in the 4th quarter valued at about $38,000. 92.80% of the stock is owned by institutional investors.

Insider Activity at Zoetis

In related news, Director Michael B. Mccallister bought 3,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Paul Bisaro bought 2,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were bought at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the purchase, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 11,650 shares of company stock valued at $886,384 in the last quarter. Insiders own 0.22% of the company’s stock.

Zoetis Stock Performance

Zoetis stock opened at $74.11 on Friday. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The stock has a market cap of $31.07 billion, a PE ratio of 12.29, a P/E/G ratio of 1.23 and a beta of 0.87. Zoetis Inc. has a 12-month low of $72.38 and a 12-month high of $172.23. The business’s 50-day moving average price is $112.28 and its two-hundred day moving average price is $120.94.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm’s revenue was up 2.9% compared to the same quarter last year. During the same period last year, the company posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, analysts expect that Zoetis Inc. will post 6.89 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ZTS shares. William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Bank of America upped their price objective on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. Citigroup initiated coverage on Zoetis in a research note on Wednesday, April 15th. They set a “buy” rating and a $145.00 target price for the company. UBS Group decreased their target price on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Finally, Stifel Nicolaus set a $105.00 price target on Zoetis in a research note on Friday, May 8th. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Zoetis has a consensus rating of “Hold” and an average price target of $137.50.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.